Sarepta Therapeutics (SRPT) to Share Expression and Safety Results from Study 103 (ENDEAVOR) Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of DMD
Go back to Sarepta Therapeutics (SRPT) to Share Expression and Safety Results from Study 103 (ENDEAVOR) Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of DMD| SAREPTA THERAP (NASDAQ: SRPT) | Delayed: 129.85 +5.60 (4.51%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $124.25 | 52 Week High | $63.73 | |||
| Open | $123.00 | 52 Week Low | $8.00 | |||
| Day High | $130.61 | P/E | N/A | |||
| Day Low | $121.80 | EPS | $-5.69 | |||
| Volume | 787,406 | |||||
